Pharmaceuticals giant Viatris Inc. on Monday announced revenue guidance below analysts’ expectations, reiterating this year would be the low point in the merged company’s results. The guidance for free cash flow and adjusted EBITDA also were below expectations.
Top officials “continue to expect 2021 to be our trough year in terms of revenue, adjusted [earnings before interest, taxes, depreciation and amortization] and free cash flow, reflecting a balanced view of both near-term tailwinds and headwinds,” CEO Michael Goettler said in a statement.
The company, which was formed late last year through the merger of Mylan with Pfizer’s Upjohn business, also announced it expects to pay an initial annual dividend of about $540 million, or roughly 44 cents per share.
Three dividend payments are expected in 2021 totaling about $400 million, the company said, with the first quarterly dividend of 11 cents per share to be declared in May and distributed in June, subject to the board’s first-quarter review.
Revenue for 2021 is expected to range from $17.2 billion to $17.8 billion, below the consensus estimate of $18.5 billion.
The company’s stock moved lower on the news, shedding $2.71 a share, or 15%, to close at $15.50 on Monday.
Read More
Research analysts at Cowen in New York were discouraged by the guidance, saying the company’s business model “appears broken.”
“We’ve long felt that standalone Mylan was broken, and we believe that rather than fixing Mylan’s problems, the Upjohn business will likely compound them,” the Cowen team wrote in an update Monday.
“Viatris’ 2021 guidance was significantly below their original expectations ... and we believe continues to highlight the rapid and difficult underlying deterioration in both [the Mylan and Upjohn] businesses,” they said.
“Neither Mylan nor Upjohn have organically grown in years, and should continue to deteriorate.”
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.